Abstract
The relapse rate in antiphospholipid syndrome (APS) remains high, i.e. around 20%–21% at 5 years in thrombotic APS and 20–28% in obstetrical APS [2, 3]. Hydroxychloroquine (HCQ) appears as an additional therapy, as it possesses immunomodulatory and anti-thrombotic various effects [4–16]. Our group recently obtained the orphan designation of HCQ in antiphospholipid syndrome by the European Medicine Agency. Furthermore, the leaders of the project made the proposal of an international project, HIBISCUS, about the use of Hydroxychloroquine in secondary prevention of obstetrical and thrombotic events in primary APS. This study has been launched in several countries and at now, 53 centers from 16 countries participate to this international trial. This trial consists in two parts: a retrospective and a prospective study. The French part of the trial in thrombosis has been granted by the French Minister of Health in December 2015 (the academic trial independent of the pharmaceutical industry PHRC N PAPIRUS) and is coordinated by one of the members of the leading consortium of HIBISCUS.
| Original language | English |
|---|---|
| Pages (from-to) | 1153-1168 |
| Number of pages | 16 |
| Journal | Autoimmunity Reviews |
| Volume | 17 |
| Issue number | 12 |
| DOIs | |
| Publication status | Published - Dec 1 2018 |
Fingerprint
Keywords
- Antiphospholipid syndrome
- Hydroxychloroquine
- Primary antiphospholipid syndrome
- Secondary prevention
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
Cite this
HIBISCUS : Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome. / Belizna, Cristina; Pregnolato, Francesca; Abad, Sebastien; Alijotas-Reig, Jaume; Amital, Howard; Amoura, Zahir; Andreoli, Laura; Andres, Emmanuel; Aouba, Achile; Apras Bilgen, Sule; Arnaud, Laurent; Bienvenu, Boris; Bitsadze, Viktoria; Blanco, Patrick; Blank, Miri; Borghi, Maria Orietta; Caligaro, Antonia; Candrea, Elisabeta; Canti, Valentina; Chiche, Laurent; Chretien, Jean Marie; Cohen Tervaert, Jan Willem; Damian, Laura; Delross, Teresa; Dernis, Emmanuelle; Devreese, Katrien; Djokovic, Aleksandra; Esteve-Valverde, Enrique; Favaro, Maria; Fassot, Céline; Ferrer-Oliveras, Raquel; Godon, Alban; Hamidou, Mohamed; Hasan, Milena; Henrion, Daniel; Imbert, Bernard; Jeandel, Pierre Yves; Jeannin, Pascale; Jego, Patrick; Jourde-Chiche, Noemie; Khizroeva, Jamilya; Lambotte, Olivier; Landron, Cédric; Latino, Jose Omar; Lazaro, Estibaliz; de Leeuw, Karina; Le Gallou, Thomas; Kiliç, Levent; Limper, Maarten; Meroni, Pier Luigi.
In: Autoimmunity Reviews, Vol. 17, No. 12, 01.12.2018, p. 1153-1168.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - HIBISCUS
T2 - Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome
AU - Belizna, Cristina
AU - Pregnolato, Francesca
AU - Abad, Sebastien
AU - Alijotas-Reig, Jaume
AU - Amital, Howard
AU - Amoura, Zahir
AU - Andreoli, Laura
AU - Andres, Emmanuel
AU - Aouba, Achile
AU - Apras Bilgen, Sule
AU - Arnaud, Laurent
AU - Bienvenu, Boris
AU - Bitsadze, Viktoria
AU - Blanco, Patrick
AU - Blank, Miri
AU - Borghi, Maria Orietta
AU - Caligaro, Antonia
AU - Candrea, Elisabeta
AU - Canti, Valentina
AU - Chiche, Laurent
AU - Chretien, Jean Marie
AU - Cohen Tervaert, Jan Willem
AU - Damian, Laura
AU - Delross, Teresa
AU - Dernis, Emmanuelle
AU - Devreese, Katrien
AU - Djokovic, Aleksandra
AU - Esteve-Valverde, Enrique
AU - Favaro, Maria
AU - Fassot, Céline
AU - Ferrer-Oliveras, Raquel
AU - Godon, Alban
AU - Hamidou, Mohamed
AU - Hasan, Milena
AU - Henrion, Daniel
AU - Imbert, Bernard
AU - Jeandel, Pierre Yves
AU - Jeannin, Pascale
AU - Jego, Patrick
AU - Jourde-Chiche, Noemie
AU - Khizroeva, Jamilya
AU - Lambotte, Olivier
AU - Landron, Cédric
AU - Latino, Jose Omar
AU - Lazaro, Estibaliz
AU - de Leeuw, Karina
AU - Le Gallou, Thomas
AU - Kiliç, Levent
AU - Limper, Maarten
AU - Meroni, Pier Luigi
PY - 2018/12/1
Y1 - 2018/12/1
N2 - The relapse rate in antiphospholipid syndrome (APS) remains high, i.e. around 20%–21% at 5 years in thrombotic APS and 20–28% in obstetrical APS [2, 3]. Hydroxychloroquine (HCQ) appears as an additional therapy, as it possesses immunomodulatory and anti-thrombotic various effects [4–16]. Our group recently obtained the orphan designation of HCQ in antiphospholipid syndrome by the European Medicine Agency. Furthermore, the leaders of the project made the proposal of an international project, HIBISCUS, about the use of Hydroxychloroquine in secondary prevention of obstetrical and thrombotic events in primary APS. This study has been launched in several countries and at now, 53 centers from 16 countries participate to this international trial. This trial consists in two parts: a retrospective and a prospective study. The French part of the trial in thrombosis has been granted by the French Minister of Health in December 2015 (the academic trial independent of the pharmaceutical industry PHRC N PAPIRUS) and is coordinated by one of the members of the leading consortium of HIBISCUS.
AB - The relapse rate in antiphospholipid syndrome (APS) remains high, i.e. around 20%–21% at 5 years in thrombotic APS and 20–28% in obstetrical APS [2, 3]. Hydroxychloroquine (HCQ) appears as an additional therapy, as it possesses immunomodulatory and anti-thrombotic various effects [4–16]. Our group recently obtained the orphan designation of HCQ in antiphospholipid syndrome by the European Medicine Agency. Furthermore, the leaders of the project made the proposal of an international project, HIBISCUS, about the use of Hydroxychloroquine in secondary prevention of obstetrical and thrombotic events in primary APS. This study has been launched in several countries and at now, 53 centers from 16 countries participate to this international trial. This trial consists in two parts: a retrospective and a prospective study. The French part of the trial in thrombosis has been granted by the French Minister of Health in December 2015 (the academic trial independent of the pharmaceutical industry PHRC N PAPIRUS) and is coordinated by one of the members of the leading consortium of HIBISCUS.
KW - Antiphospholipid syndrome
KW - Hydroxychloroquine
KW - Primary antiphospholipid syndrome
KW - Secondary prevention
UR - http://www.scopus.com/inward/record.url?scp=85055894621&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85055894621&partnerID=8YFLogxK
U2 - 10.1016/j.autrev.2018.05.012
DO - 10.1016/j.autrev.2018.05.012
M3 - Review article
VL - 17
SP - 1153
EP - 1168
JO - Autoimmunity Reviews
JF - Autoimmunity Reviews
SN - 1568-9972
IS - 12
ER -